Janssen COVID-19 vaccine becomes 3rd authorized in U.S.
Janssen Biotech's COVID-19 vaccine has received an emergency use authorization from the U.S. Food and Drug Administration. The move allows the vaccine to be distributed in the U.S. for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 18 years of age or older. Read More
FDA committee gives nod to Janssen COVID-19 vaccine
A single-shot COVID-19 vaccine from Johnson & Johnson's Janssen Biotech subsidiary received a positive recommendation today from a U.S. Food and Drug Administration (FDA) advisory committee. Should the FDA grant the product emergency use authorization, the vaccine candidate will become the third to be made available in the U.S. Read More
New open-access toolkit helps research labs study SARS-CoV-2
One of the most important factors in fighting the COVID-19 pandemic is large-scale scientific collaborations and knowledge sharing. One international group of researchers has made its simple, robust toolkit available to laboratories around the globe that are unaccustomed to working with coronaviruses. The details can be found in a PLOS Biology paper published on February 25. Read More
New England Biolabs supports SARS-CoV-2 monitoring with NGS kits
New England Biolabs has launched three next-generation sequencing (NGS) kits based on Artic Network protocols for multiplexed amplicon-based sequencing of viral RNA. Read More
U.S. purchases another 100K doses of Lilly COVID-19 antibodies
The U.S. government is purchasing a minimum of 100,000 doses of Eli Lilly's bamlanivimab 700 mg and etesevimab 1,400 mg together, which are neutralizing antibodies that can treat mild to moderate COVID-19 in patients who are at high risk of progressing to a severe stage. Read More
Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many biopharmaceutical companies are continuing to push new vaccine candidates toward regulatory approval. The slow rollout of approved vaccines has created the need for second-generation products with the potential to accelerate the world's return to something approaching normalcy. Read More
Altimmune begins trial of nasal COVID-19 vaccine
Altimmune has begun enrollment in a phase I clinical trial of AdCOVID, a single-dose, intranasal COVID-19 vaccine candidate. Read More
Pfizer, BioNTech study 3rd booster of vaccine to protect against variants
Pfizer and BioNTech have started the evaluation of the safety and immunogenicity of a third dose of their COVID-19 vaccine BNT162b2 as a booster on immunity against COVID-19 caused by emerging SARS-CoV-2 variants. Read More
Moderna addresses SARS-CoV-2 variants, ramps up vaccine production
Moderna is pursuing two strategies against emerging SARS-CoV-2 variants. The company is evaluating booster vaccine doses and is increasing vaccine manufacturing capacity to meet global demand. Read More
Game theory reveals how SARS-CoV-2 tricks human cells
Researchers have applied game theory in an effort to understand how SARS-CoV-2 mimics host proteins to support its own replication. The work, published in Royal Society Interface on February 24, applied a type of game theory on how information is signaled to reveal how the virus tries to trick human cells from attacking it. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter